(1) Schedule 1 to the principal Order (which specifies the class of medicinal products, other than products the subject of a product licence of right, on general sale by virtue of article 2(a) of the principal Order) is amended in accordance with the following provisions of this article.
(2) In Table A (internal and external use)—
(a) against the entry in column 1 for “Lignocaine” —
(i) there is substituted in column 2 for the entry “(2) 0.6 per cent”, the entry “(2) 2.0 per cent”, and
(ii) there are inserted in column 3, after the words “except local ophthalmic use”, the words “, for use in adults and in children aged 12 years and over”;
(b) there are deleted the entry “Phenolphthalein” in column 1 and the corresponding text “120 mg (MD)” in column 4; and
(c) there are inserted in column 1, at the appropriate point in the alphabetical order of the entries as they appear in that column, each of the entries set out in column 1 of Schedule 1 to this Order, and against the entry “Potassium Chloride” inserted in column 1 by virtue of this sub-paragraph, there is inserted in columns 2 and 3 the corresponding text in columns 2 and 3 of Schedule 1 to this Order.
(3) In Table B (external use only)—
(a) there are inserted in column 1, at the appropriate point in the alphabetical order of the entries as they appear in that column, each of the entries set out in column 1 of Schedule 2 to this Order; and
(b) against the entry “Benzocaine” inserted in column 1 by virtue of this paragraph, there is inserted in columns 2 and 3 the corresponding text in columns 2 and 3 of Schedule 2 to this Order.